Ampelotherapy for Health & Longevity - Quick Reference Sheet

Ampelotherapy for Health & Longevity

Created on 08/27/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 Audit

Grapes as most or all of the diet for weeks. Grape products modestly lower the upper blood-pressure number, improve insulin handling, and reduce excess weight; in lean, healthy adults that upside nears zero. The classical diet strips protein and fat, adds heavy potassium and sugar, has never been tested as a whole, and can displace effective cancer treatment. (Full Review)

Protocol

Daily Amount
1.5–3 kg
Classical spa course, built up from 0.5 kg over a week; sanatorium courses 1–2 kg. The evidence-informed alternative is 250–350 g alongside a complete diet.
Course Length
3–6 weeks
Classical spa length. Brandt's cure ran 1–2 weeks after a 2–3 day water fast; sanatorium courses 3–4 weeks.
Timing
Split, before meals
Weighted toward the morning, stopping three hours before sleep. A single kilogram portion exceeds gastric capacity and the intestinal fructose threshold.
Time to effect
Blood Pressure
4–12 weeks
The window in controlled trials — longer than most historical grape courses ran.
Verbal Memory
12 weeks
Verbal learning improved in older adults with memory decline short of dementia; the trial used juice, not whole grapes.
Bowel & Appetite
1–3 days
The first changes to appear. Relief of chronic constipation was the traditional spa indication; no controlled trial has tested it.

Benefits

Contraindications
  • SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) during any fasting phase
  • Type 1 diabetes, and insulin-treated type 2 diabetes outside specialist supervision
  • Chronic kidney disease stage 4 or 5 (eGFR below 30 mL/min/1.73 m²), or serum potassium above 5.0 mmol/L
  • Active malignancy under curative-intent treatment
  • Hereditary fructose intolerance (two defective ALDOB copies)
  • Documented grape or lipid transfer protein allergy
  • Body mass index below 18.5 kg/m², unintentional weight loss above 5% within six months, or any diagnosed eating disorder
  • Pregnancy and lactation
  • Adults over seventy-five with sarcopenia or a usual gait speed below 0.8 m/s
  • Decompensated cirrhosis (Child-Pugh Class C)
Key Interactions
  • Insulin and sulfonylureas (glipizide, glyburide)
  • Renin-angiotensin blockers and potassium-sparing diuretics (lisinopril, losartan, spironolactone, amiloride)
  • Warfarin
  • Digoxin
  • Aspirin and other non-steroidal anti-inflammatory drugs (ibuprofen, naproxen)
  • Antacids and proton pump inhibitors (omeprazole, esomeprazole)
  • Salt substitutes and oral rehydration salts (potassium chloride)
  • Potassium and magnesium supplements
  • Grape seed extract and resveratrol supplements
  • Quercetin, curcumin and fish oil
  • Blood-pressure-lowering supplements (beetroot nitrate, hibiscus, garlic, cocoa flavanols)
  • Prolonged fasting and ketogenic diets
  • GLP-1 receptor agonists (semaglutide, tirzepatide)

Risk & Side Effects

  • High: Elevated fasting blood glucose
  • Medium: Osmotic diarrhea, bloating and cramping; delayed or forgone effective cancer treatment
  • Low: Protein-energy deficit and lean mass loss; refeeding electrolyte shifts; hyperkalemia in reduced kidney function; fructose-driven uric acid rise and gout; immediate hypersensitivity reactions
  • Speculative: Dental enamel erosion; agrochemical and mycotoxin load

Monitoring

Marker Target Why
Potassium 4.0–4.5 mmol/L Grape intake adds grams of potassium daily
Estimated glomerular filtration rate (eGFR) Above 90 mL/min/1.73 m² Decides whether the potassium load is excreted or accumulates
Fasting glucose 75–86 mg/dL Tracks the sugar load most directly
Glycated hemoglobin (HbA1c) 4.8–5.4% Captures cumulative glucose exposure across a whole course
Uric acid 3.5–5.5 mg/dL (men), 3.0–5.0 mg/dL (women) Fructose raises urate production
Triglycerides Below 80 mg/dL Fructose drives liver fat synthesis
Albumin 4.2–5.0 g/dL Coarse marker of protein adequacy
Fat-free mass No established target; track change from own baseline, a fall above 2% across a course is meaningful The outcome most likely to be harmed by the regimen
Phosphate 3.0–4.0 mg/dL Falls sharply during refeeding
Magnesium (red blood cell) 5.0–6.5 mg/dL Shifts with phosphate during refeeding
High-sensitivity C-reactive protein (hs-CRP) Below 0.5 mg/L Baseline inflammation, on which pooled trials of grape polyphenols disagree
Home blood pressure Below 120/80 mmHg The one endpoint with pooled trial support

Cadence: Full panel at baseline. During a course, potassium, creatinine and fasting glucose at day seven and at the end; blood pressure daily; phosphate and magnesium through the refeeding week. Four weeks after finishing, the full baseline panel and body-composition measurement are repeated, then every six to twelve months where courses recur annually.

Qualitative Assessment

  • Energy and physical capacity: whether usual training loads and daily tasks still feel normal, which degrades before albumin does
  • Bowel pattern: stool frequency and form, the earliest and most reliable signal that the fructose load has exceeded tolerance
  • Hunger and food preoccupation: persistent intrusive thoughts about food indicate the energy deficit has moved past useful
  • Sleep quality: subjective depth and continuity, which fall with both nocturnal glucose swings and sustained restriction
  • Cognitive clarity: concentration and working memory during ordinary tasks, which blur under energy restriction